Our results support the use of CYR61 and TAZ as early biomarkers to discriminate which BE patients have an increased risk to progress to dysplasia and cancer and further suggest that proteins/genes involved in EMT are critical to trigger the BE lesions that evolve to more aggressive lesions. The gene discussed is CCN1; the disease is Barrett esophagus.